National Health Service patients in the UK will be the first to gain access in Europe to new skin cancer treatment, Libtayo (cemiplimab), through the Cancer Drugs Fund (CDF), it was revealed today, just a day after the drug won conditional regulatory approval from the European Commission.
French pharma major Sanofi (Euronext: SAN), which has developed the product in partnership with US biotech Regeneron Pharmaceuticals (Nasdaq: REGN), today announced that the National Institute for Health and Care Excellence (NICE) has published a positive Final Appraisal Determination (FAD) recommending Libtayo as an option for treating metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) in adults when curative surgery or curative radiation is not appropriate.
According to a Sanofi statement:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze